Dr. Lauren Stevenson

Immunologix Laboratories Appoints Lauren Stevenson, Ph.D. As Chief Scientific Officer And Further Expands Translational Sciences Drug Development Expertise

TAMPA, Fla., — Immunologix Laboratories announces the appointment of Lauren Stevenson, Ph.D. as Chief Scientific Officer and further expands the Translational Sciences team, as Christopher Stebbins, Ph.D. joins the drug development experts as Scientific Director. Ensuring strong leadership and continuous scientific growth is a key objective for the organization.

“With Dr. Stevenson as Chief Scientific Officer, we are excited about the enhanced scientific and strength-focused team leadership she is bringing to our organization, as well as accelerating our industry-impacting initiatives,” notes Immunologix Laboratories President and CEO, Dr. Michael Anderson. “We are already seeing immediate and demonstrated benefits for both our clients and internal scientists as she builds upon her deep strategic, scientific and results-oriented experience. Dr. Stevenson’s appointment further strengthens our industry leading scientific leadership team.”

A globally recognized thought leader, Dr. Stevenson is leveraging her 25+ years of drug development experience, which spans numerous disease indications and drug modalities. In this role, she will ensure science-first collaborations with clients to deliver proven strategy and results, while also maximizing synergies between Immunologix’s assay experts and the Translational Sciences Directors. Dr. Stevenson joined Immunologix Laboratories in April 2019, following her post as Senior Director & Head, Development Biomarkers & Bioanalytical Sciences at Biogen (Cambridge, MA). Together, with Dr. Devangi Mehta, she co-founded Translational Sciences in May 2019 and will continue to lead that function as part of her new role.

Dr. Stevenson commented, “I’m truly honored and humbled to take on this expanded role for Immunologix Laboratories and am fully committed to building a partnership model for our clients that is unique in the industry. In parallel, I’m equally excited and enthusiastic about growing our internal scientific community and building upon our culture of high science, collaboration and interdependence that maximizes opportunities to continuously learn from one another.”

Concurrently, Immunologix Laboratories welcomes Dr. Christopher Stebbins to the Translational Sciences team. Bringing two decades of drug development experience in large pharma/biotech, with expertise in building and executing on strategies for both biomarker and bioanalytical development, Dr. Stebbins joins from his previous post as Director, Development Biomarkers & Bioanalytical Sciences at Biogen (Cambridge, MA).

The Translational Sciences team of Immunologix Laboratories provides a dedicated partner and resource to advise, develop, and implement integrated strategies and solutions for innovator development programs from discovery to post-market. The expert team delivers stage appropriate biomarker, bioanalytical and clinical research strategies, scientific oversight of assay lifecycle management, study data analysis and interpretation, as well as support for regulatory interactions and document writing.

“The pace of growth across Translational Sciences has exceeded our expectations,” Dr. Stevenson comments. “This speaks to the demand for experts who can deliver across all stages of drug development and traverse the bioanalytical, biomarker and regulatory arenas with equal facility. With the addition of Dr. Stebbins, our Translational Sciences team, which also includes VP of Biomarker Sciences, John Allinson, now brings more than 100 years of collective experience to bear on our clients’ projects. Combined with our exceptional technical and laboratory expertise, we are redefining the CRO partnership landscape for our clients around the world.”

Dr. Stevenson will be presenting on “Preventing Misguided Guidance – Putting Biomarker Assay Validation in Context” on April 23, 2020 as part of Immunologix Laboratories’ webinar series. Registration for the event can be found here. To learn more about Immunologix Laboratories full capabilities and explore learning opportunities offered by the expert scientific team, visit www.immunologixlabs.com

About Immunologix Laboratories
Immunologix Laboratories is a unique scientific partner, offering GLP and GCP compliant laboratory capabilities focused on ligand binding based bioanalysis coupled with expert scientific consultation from our Translational Sciences team. Our laboratory specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding based), PK, and Biomarker assays in support of preclinical and clinical studies. Translational Sciences provides dedicated scientific resources to advise, develop and implement scientific strategies and practical solutions for innovator development programs. Our fully customizable approach includes delivering stage appropriate biomarker & bioanalytical strategies, assay development and validation, study data interpretation and support for regulatory interactions and filings. Our exceptional scientific experts work together as an integrated team ensuring that our client’s projects receive full benefit of the breadth and depth of experience gained over many decades within both contract laboratory and drug development organizations. The integration of Translational Sciences with the laboratory is unique within our industry and this confluence of expertise enables our team to deliver valuable scientific insights that can accelerate decision making and the course of drug development.

PRESS CONTACT INFORMATION
Michael J. Anderson
President and CEO, Immunologix Laboratories
1.813.324.1483
manderson@immunologixlabs.com

Immunologix Laboratories Adds Accomplished Biotech Drug Development Experts To Launch Translational Sciences Division

Tampa, FL

With the launching of their Translational Sciences division, Immunologix Laboratories continues to strengthen it’s scientific and technical expertise to build an industry-leading drug development partner for clients and their bioanalytical and biomarker programs.

The new Translational Sciences team is led by Dr. Lauren Stevenson, following her post as Senior Director & Head, Development Biomarkers & Bioanalytical Sciences at Biogen (Cambridge, MA). She is joined by Dr. Devangi Mehta, who most recently served as Director, Development Biomarkers and Bioanalytical Sciences at Biogen. Both globally recognized thought leaders, Drs. Stevenson and Mehta will leverage their 40+ years of collective drug development experience, which spans numerous disease indications and drug modalities, to create enhanced synergy with Immunologix’s assay experts and deliver proven strategy and results for clients.

The Translational Sciences division will provide a dedicated partner and resource to advise, develop, and implement integrated strategies and solutions for innovator development programs from discovery to post-market, delivering stage appropriate biomarker, bioanalytical and clinical research strategies, scientific oversight of assay lifecycle management, study data analysis and interpretation, and supporting regulatory interactions and document writing. Drs. Stevenson and Mehta come with significant performance records that include both internal program successes through product launch, as well as data-driven influencing of regulatory guidance and industry best practices.

Dr. Stevenson commented: “I am truly excited and privileged to lead the Translational Sciences division and am looking forward to building a world class team of drug developers with deep biomarker and bioanalytical experience. Together we will pioneer a new model of scientific support that will actively leverage the diverse perspectives and expertise of the team to deliver highly vetted, pressure-tested strategies and scientific solutions to our clients.”

Immunologix President and CEO Dr. Michael Anderson adds: “We are very excited to announce the launch of our Tanslational Sciences division. The addition of Lauren and Devangi gives us an unparalleled, industry-leading assay strategy and implementation team. By combining their experience with that of John Allinson, our Vice President of Biomarker Services, and other members of our very experienced senior staff, we can offer our clients a level of scientific service that is unmatched in the bioanalytical lab industry.“

About Immunologix Laboratories
Immunologix Laboratories is a science-based GLP and GCP compliant immunoassay laboratory focused on ligand binding based bioanalysis and biomarkers. The lab specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding-based), PK, and Biomarker assays in support of preclinical and clinical trials. The Translational Sciences division provides enhanced experienced resources for technical strategy and implementation of bioanalytical and biomarker assays. Immunologix’s customer-focused service model allows it to customize project execution for each client in a timely manner. The entire team has many years of CRO and industry experience in development, validation, and application of immunoassay-based methods.

 

PRESS CONTACT INFORMATION
Michael J. Anderson
President and CEO, Immunologix Laboratories
1.813.324.1483
manderson@immunologixlabs.com

Biologics Development Services Becomes Immunologix Laboratories

Biologics Development Services becomes Immunologix Laboratories.
Immunologix Laboratories

Immunogenicity For Biotherapeutics

Advance Risk Assessment Strategies and Optimize the Prediction of Immune Response to Accelerate the Process from Concept to Approval

WCBNoTag

Improve your drug safety analysis with improved,
specific, and accurate immunogenicity information
so you can minimize the time it takes to gain
regulatory approval and increase speed to market


  • Hear firsthand perspectives from the FDA to gain insights and ask your questions to accelerate the approval process
  • Collaborate with peers and industry experts to develop solutions for predicting, anticipating, and mitigating risks created by potential immune responses
  • Discover cutting-edge technologies to improve immunogenicity testing
  • Improve the accuracy of your risk assessment by understanding how protein aggregation impacts immunogenic responses

Download Your
Copy Today!



B15193minibrochure


“An excellent program – extremely useful from a technical
perspective. The lessons from the case studies and discussions
will assist our group’s development efforts.”
– Thomas Klem, Scientist, Shire

 


Use Priority Code IMMUNO15BDS to Save 20%


Group Savings Available for Companies Registering 4+ Attendees

Register Now

Welcome to BDS: Biologics Development Services

Biologics Development Services (BDS) announced today the opening of their immunoassay laboratory in the Westshore area of Tampa, Florida. BDS provides large molecule bioanalytical services of the highest caliber to pharmaceutical and biotechnology companies across the United States. Because there is an art as well as science to immunoassay, BDS offers you the distinct advantage of management by one of the industry’s most noted experts. Equally advantageous is the fact that BDS has the expertise to develop unique reagents and de novo assays to further your company’s drug development program.